In human cancer, the PI3K pathway (PI3K-AKT-mTOR) is most activated by PI3Kα mutation, overexpression of growth factor receptors with tyrosine kinase activity and PTEN gene inactivation. This evidence concerns the gene PIK3CD and cancer.